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Introduction
There is little debate that chorioamnionitis (CAM),
which is an ascending infection from bacterial vaginosis
and cervicitis, results in preterm delivery [1]. As there are
many reports of CAM-induced preterm delivery, it is
conceivable that the key to preterm delivery prevention
is CAM prevention. Prior attempts to prevent preterm
delivery focused on early detection and treatment of
bacterial vaginosis and cervicitis, which was thought to
be the stage before CAM.
There have been many negative reports of the
efficacy of preterm delivery prevention by antibiotic
administration, since disruption of normal vaginal
bacteria (e.g. Lactobacillus) is probably one of the
problems. In prevention of preterm delivery caused by
CAM, prebiotic-like treatment, which returns vaginal
bacterial flora to normal healthy proportions, reduces
the production of inflammatory cytokines and has no
side effects. LF, a prebiotic that has antibacterial and
anti-inflammatory actions, accompanies the sugar pro-
tein and is found in mother’s milk, leukocytes, cervical
SUMMARY
Objective: Chorioamnionitis (CAM), an ascending infection from maternal bacterial vaginosis or cervicitis, can
cause preterm delivery. We hypothesized that lactoferrin (LF), in particular recombinant human LF (rh-LF),
may prevent preterm delivery. We conducted three experiments to demonstrate LF’s ability to prevent preterm
delivery.
Materials and Methods: First, we correlated human cervical mucus LF concentration and LF and interleukin-
6 (IL-6) concentrations in amniotic fluid to gestational weeks, in mothers with and without CAM. Second,
using an amnion cell culture system, we studied the preventive effect of rh-LF on inflammatory cytokine
production induced by lipopolysaccharide. Using human cervical gland cell lines, we studied the preventive
effects of rh-LF on the growth of Escherichia coli. Thirdly, we studied the preventive effect of rh-LF in mouse
and rabbit models of preterm delivery. We also examined LF’s preventive effect on the production of inflammatory
cytokines in maternal serum and amniotic fluid.
Results: In mothers with CAM, amniotic fluid LF concentrations were elevated and IL-6 production increased
as fetal LF levels and inflammation increased. LF administration prevented IL-6 production, demonstrating
LF’s anti-cytokine action and control over E. coli. Length of pregnancy was extended and fetal survival rates
were higher in mothers who received LF.
Conclusion: It appears that LF is highly beneficial in the prevention of preterm delivery and improving poor
fetal prognosis due to elevated inflammatory cytokine levels. Specifically, rh-LF may prevent the production
of inflammatory cytokines under E. coli infection or control maternal cytokine production. [Taiwanese J Obstet
Gynecol 2005;44(2):123–127]
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mucus, semen, amniotic fluid, and other external fluids
[2–4]. The presence of LF modifies the body’s immune
function and defends against bacterial invasion.
Specifically, LF binds to intracellular membrane pro-
teins and controls bacterial proliferation by binding
the available iron needed for bacterial development,
thus exerting an effective antibacterial action by de-
stroying bacterial cell membranes. LF also assists the
specialization of natural killer cells and lymphocytes,
and in phagocytosis by leukocytes and macrophages. LF
is discharged from leukocytes to the site of infection,
controlling migration and vitalization by adjusting
cytokine production. LF controls phagocyte oxygen
production and subsequent oxidative injury.
In order to determine LF’s potential in the prevention
of preterm delivery, we examined the following: LF’s
movement in cervical mucus, to determine its clinical
efficacy; the antibacterial and anti-cytokine effects of LF
in human cell culture systems; and the preventive effects
of recombinant human LH (rh-LF) on preterm delivery
(Figure 1).
LF Production and Secretion in Human
Cervical Mucus and Amniotic Fluid
We examined the presence of LF in cervical mucus and
amniotic fluid. To collect the cervical mucus and
amniotic fluid, aprotinine, sodium azide (NaN3), and
phosphate-buffered saline (PBS) were added and then
anti-human LF IgG polyclonal antibody was used.
Changes associated with the specific gestational week
were examined. Amniotic fluid samples were also
obtained by transabdominal amniocentesis or upon
delivery. Twenty-one samples of amniotic fluid (32–39
weeks of gestation) from normal deliveries without
amniotic infection were also obtained as controls.
Cervical mucus and amniotic fluid samples were
centrifuged and the supernatant was stored at –80ºC
until assay using a sandwich enzyme-linked immuno-
sorbent assay (ELISA). Inter- and intra-assay coefficients
of variation were 4.7% and 7.0%, respectively.
This study was approved by the ethics committee,
and patients gave consent before samples were ob-
tained. Similarly, animal experiments were conducted
under the approval of the animal experiment control
committee.
LF concentration in cervical mucus from controls
was 8.0 ( 11.0 +g/mL, from patients with bacterial
vaginosis was 16.3 ( 13.5 +g/mL, and from patients
with cervicitis was 15.7 ( 13.4 +g/mL. LF concentration
in the bacterial vaginosis group was significantly lower
than that in the control group (p < 0.05) (Figure 2). The
concentrations of LF and IL-6 in amniotic fluid from
CAM cases (n = 28) were 8.76 ( 0.65 and 6.92 ( 4.88
+g/mL, respectively, and both were significantly higher
than in amniotic fluid from those without CAM (n = 31;
0.86 ( 0.81 and 0.34 ( 0.25 +g/mL, respectively;
p < 0.01). There was a significant positive correlation
between LF and IL-6 levels in amniotic fluid (r = 0.91,
p < 0.01) (Figure 3).
These results show that human cervical cells produce
LF and that this production is accelerated during
pregnancy. The LF concentration in cervical mucus from
patients with bacterial vaginosis or cervicitis was high,
meaning that LF production by cervical cells was reduced
by inflammation or infection, thus promoting infection
and reducing host defenses. This shows that LF has an
anti-inflammatory function. On the other hand, LF
production in the newborn is increased by inflammation,
suggesting that the amniotic LF concentration was high
in the CAM group. In addition, a newborn CAM case
had a high salivary LF concentration (data not shown).
Thus, LF is involved in the anti-inflammatory reaction of
the fetus.
Figure 1. Physiologic activity of lactoferrin (LF). NK = natural
killer.
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Figure 2. Lactoferrin (LF) concentration in cervical mucus of
pregnant women. Each column represents the concentration
of LF in cervical mucus. Group A: no complications (n = 68);
group B: bacterial vaginosis (n = 17); group C: cervicitis (n =
32). *p < 0.05 versus group A.
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Antibacterial and Anti-inflammatory
Cytokine Action of LF
The preventive effect of LF on inflammatory cytokine
production in amniotic cell culture and bacterial growth
in cervical cell lines were examined.
Amniotic cell culture
Confluent primary amniotic cell cultures (7–10 days)
were dispersed using 0.5% trypsin, placed in six-well
culture dishes in serum-free Dulbecco’s modified Eagle
medium (D-MEM)/F12 containing 1% Ab/Am, and the
cells were incubated for 24 hours. Lipopolysaccharide
(LPS) and/or LF was then added to the medium. After
further incubation, the culture medium was collected
and the IL-6 concentration was measured using a human
IL-6 ELISA kit (Fuji Revio, Tokyo, Japan) [5–7].
IL-6 production was induced by LPS (100 ng/mL) in
cultured amnion cells to levels approximately five times
that of the control cells. This induced production was
significantly inhibited by LF, depending on the dose
(p < 0.05). Inhibitory levels were well within physio-
logic LF concentrations (1 +g/mL). A similar tendency
was observed in all other experiments using amniotic
membranes (Figure 4).
Cervical cell lines
Two human cervical epithelial cell lines, ME-180 (a non-
mucus producing cell, ATCC HTB-33) and HeLa (a
mucus-producing cell, ATCC CCL-2) were used. No
therapy was used in these studies. The bacterial
pathogen, Escherichia coli (ATCC EC-5), was used for
inoculation and then isolated from a human infant.
Treatment was added at the time of infection. After 2
hours’ incubation, the supernatant was cultured using
standard pour-plate techniques. Thereafter, the cells
were disrupted and cultured using the same methods.
Treatment with rh-LF was used to examine its
antibacterial action towards E. coli [8].
It has been suggested that mucus-producing cervical
cells play an important role while non-mucus producing
cells do not. In the presence of rh-LF, mucus-producing
cervical epithelial cells may play an important role in
restricting bacterial growth, since rh-LF controlled E. coli
development in mucus-producing cells (Figure 5).
Our results demonstrate the anti-cytokine function
of LF in human amnion cell culture. The antibacterial
function appeared only in mucus-producing cervical
cells. It is thought that LF is activated by cytokine and
macrophage production, while it is reduced in the
presence of E. coli.
Preventive Effect of LF on Preterm Delivery
in Animal Models
Mouse model
We conducted this study under the approval of the
animal experiment committee of our institution. Female
C3H/HeNCrj mice were pair-mated with male Crj:
B6D2F1 mice. On day 15 of gestation, as a model of
Figure 3. Lactoferrin (LF) and interleukin-6 (IL-6) concentrations in amniotic fluid from pregnant women with (+; n = 28) and
without (–; n = 31) chorioamnionitis (CAM). Mean ( standard deviation. *p < 0.01 versus CAM(–).
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Figure 4. Effect of lactoferrin (LF) on lipopolysaccharide
(LPS)-induced interleukin-6 (IL-6) production in amniotic cells.
Mean ( standard deviation of three culture dishes. *p < 0.05
versus control.
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preterm delivery, a 50-+g/kg intraperitoneal injection of
LPS was administered twice with a 3-hour interval
between injections (2:00 and 5:00 pm). One hour prior
to each LPS injection (1:00 and 4:00 pm), an intra-
peritoneal injection of saline with bovine LF (b-LF) or
rh-LF (1 mg/body) was administered. In non-LPS-
treated controls, an intraperitoneal injection of saline
was administered at four times (1:00, 2:00, 4:00, and
5:00 pm). Body weight and delivery time were recorded.
To measure plasma levels of IL-6 and tumor necrosis
factor-_ (TNF-_), other pregnant mice, prepared as
above, were sacrificed 6 hours after the second LPS
injection. Blood samples were obtained and analyzed as
described previously [9–11].
All non-LPS-treated mice had term delivery at 19 ( 0
gestational days. All LPS-treated mice that did not
receive LF had preterm delivery at 1.2 ( 0.4 days after the
second LPS injection (16.2 ( 0.4 gestational days).
Administration of b-LF or rh-LF to LPS-treated mice
significantly prolonged gestation to 17.8 ( 0.3 and
18.2 ( 1.3 gestational days, respectively (p < 0.05). All
deliveries occurred without maternal death. All pre-
term deliveries at less than 17 days’ gestation were still-
births while, in contrast, those at 17 gestational days
or later were live births. Plasma IL-6 concentration was
significantly higher in LPS-treated mice that did not
receive LF (1,628 ( 115 pg/mL) than in non-LPS-treated
mice (497 ( 39 pg/mL; p < 0.05). Administration of b-
LF or rh-LF to LPS-treated mice significantly suppressed
plasma IL-6 levels to 1,060 ( 154 and 244 ( 59 pg/mL,
respectively (p < 0.05). Plasma TNF-_ concentration
was significantly higher in LPS-treated mice that did not
receive LF (114 ( 49 pg/mL) than in non-LPS-treated
mice (p < 0.05). Administration of b-LF or rh-LF to LPS-
treated mice significantly suppressed plasma TNF-_
levels to 88 ( 6 and 38 ( 30 pg/mL, respectively (p <
0.05) (Figures 6–8).
Rabbit model
We conducted this study under the approval of the
animal experiment committee of our institution. Timed
pregnant, New Zealand White rabbits (3–4 kg) were
anesthetized with an intramuscular injection of ketamine
hydrochloride and inoculated with 0.2 mL of E. coli (107
colony forming units, CFU/body) or saline solution
using a sterile polyethylene cannula (1.2 mm outer
diameter) and an hysteroscope. The rabbits were ran-
domly assigned to one of three groups: A (n = 3) re-
ceived sterile saline plus sterile saline, B (n = 8) received
sterile saline plus E. coli, and group C (n = 7) received rh-
LF (5 mg/body) 2 hours before inoculation with E. coli.
Figure 5. Antibacterial effect of recombinant human lactoferrin
(rh-LF) on human cervical epithelial cells. Each column
represents the percent control of bacteria, where 100% of the
value is used as the control for each condition without any
treatment (no LF). “No cells” means no epithelial cells and only
Escherichia coli cells were present. The next two bars are HeLa
and ME-180 cells with E. coli per epithelial cells: control, n = 5;
HeLa, n = 5; MB-180. *p < 0.05 versus control.
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Figure 7. Effect of recombinant human lactoferrin (rh-LF) on
plasma interleukin-6 (IL-6) in pregnant mice. Each column
represents plasma IL-6, 6 hours after the second lipopoly-
saccharide (LPS) treatment: LPS without LF, n = 12; LPS +
bovine LF (b-LF), n = 12; LPS + rh-LF, n = 7; non-LPS-treated,
n = 12. Values are expressed as pg/mL. *p < 0.05 versus LPS
without LF.
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Figure 6. Effect of recombinant human lactoferrin (rh-LF) on
gestational duration. Each column represents the number of
gestational days after the second lipopolysaccharide (LPS)
treatment: LPS without LF, n = 14; LPS + bovine LF (b-LF), n =
14; LPS + rh-LF, n = 12; non-LPS-treated, n = 12. *p < 0.05
versus LPS without LF.
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Figure 8. Effect of recombinant human lactoferrin (rh-LF) on
plasma tumor necrosis factor-_ (TNF-_) in pregnant mice.
Each column represents plasma TNF-_, 6 hours after the
second lipopolysaccharide (LPS) treatment: LPS without LF,
n = 12; LPS + bovine LF (b-LF), n = 12; LPS + rh-LF, n = 7; non-
LPS-treated, n = 12. Values are expressed as pg/mL. *p < 0.05
versus LPS without LF.
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We measured TNF-_ concentrations in both maternal
serum and amniotic fluid.
In the rabbit experiment, fetal survival rates were
95.7% (group A), 0% (group B) and 32.6% (group C).
The survival rate in group C was significantly higher
than that in group B (p < 0.01). Pregnancy continued for
7.00 ( 0 days from inoculation in group A, 3.25 ( 0.43
days in group B, and 4.85 ( 1.77 days in group C.
Pregnancy duration from inoculation in group C was
significantly longer than that in group B (p < 0.05).
TNF-_ concentrations in serum at birth decreased, al-
though group C did not significantly differ in contrast
to group B. TNF-_ concentrations in amniotic fluid
at birth also decreased, although group C did differ
in comparison with group B.
These results clearly show that LF prevents preterm
delivery in animals. This effect is due to maternal cytokine
production in the amnion, placenta, and other tissues.
On the other hand, the fetus death rate among rabbits
that received LF in the E. coli-induced preterm delivery
model was low. This demonstrates that LF can improve
the poor prognosis of a fetus subject to inflammatory
cytokines, which often results in spontaneous abortion.
LF, a beneficial protein existing at high amounts in
humans, has fewer side effects than expected.
Conclusion
These results show that rh-LF originating in mucus-
producing cervical cells had both antibacterial and anti-
cytokine actions. LF controlled inflammation and fetal
survival in preterm delivery animal models. Thus, LF was
clinically effective in preventing preterm delivery.
The present study examined the ability of rh-LF to
prevent preterm delivery caused by bacterial infection.
These findings support the clinical application of rh-LF
in the prevention of preterm births via the suppression
of inflammatory cytokine production.
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